Cited by 506Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchCancer Genomics and Diagnostics

The DOI matches its Crossref record; 46 of the 48 references it cites were found in a registry or an index.

Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 ( HER2 ) Tyrosine Kinase Mutations in Lung Adenocarcinomas

Open access

Arcila, Maria E., Chaft, Jamie E., Nafa, Khedoudja, Roy-Chowdhuri, Sinchita, Lau, Christopher, Zaidinski, Michael, Paik, Paul K., Zakowski, Maureen F., Kris, Mark G., Ladanyi, Marc·2012·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-12-0912PMC PMC3865806

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Purpose: Activating mutations in the tyrosine kinase domain of HER2 (ERBB2) have been described in a subset of lung adenocarcinomas (ADCs) and are mutually exclusive with EGFR and KRAS mutations. The prevalence, clinicopathologic characteristics, prognostic implications, and molecular heterogeneity of HER2-mutated lung ADCs are not well established in U.S. patients. Experimental Design: Lung ADC samples (N = 1,478) were first screened for mutations in EGFR (exons 19 and 21) and KRAS (exon 2), and negative cases were then assessed for HER2 mutations (exons 19–20) using a sizing assay and mass spectrometry. Testing for additional recurrent point mutations in EGFR, KRAS, BRAF, NRAS, PIK3CA, MEK1, and AKT was conducted by mass spectrometry. ALK rearrangements and HER2 amplification were assessed by FISH. Results: We identified 25 cases with HER2 mutations, representing 6% of EGFR/KRAS/ALK-negative specimens. Small insertions in exon 20 accounted for 96% (24/25) of the cases. Compared with insertions in EGFR exon 20, there was less variability, with 83% (20/24) being a 12 bp insertion causing duplication of amino acids YVMA at codon 775. Morphologically, 92% (23/25) were moderately or poorly differentiated ADC. HER2 mutation was not associated with concurrent HER2 amplification in 11 cases tested for both. HER2 mutations were more frequent among never-smokers (P < 0.0001) but there were no associations with sex, race, or stage. Conclusions: HER2 mutations identify a distinct subset of lung ADCs. Given the high prevalence of lung cancer worldwide and the availability of standard and investigational therapies targeting HER2, routine clinical genotyping of lung ADC should include HER2. Clin Cancer Res; 18(18); 4910–8. ©2012 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-12-0912

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W. J., Jones, L. A., Holt, J. A., Wong, S., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J. A., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,817
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
Grávalos, C., & Jimeno, A. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn169 · Cited by 1,205
A Hierarchical Network of Interreceptor Interactions Determines Signal Transduction by Neu Differentiation Factor/Neuregulin and Epidermal Growth Factor
Tzahar, E., Waterman, H., Chen, X., Levkowitz, G., Karunagaran, D., Lavi, S., Ratzkin, B. J., & Yarden, Y. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5276 · Cited by 1,039
Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
Gazdar, A. F. (2009) · Oncogene · doi:10.1038/onc.2009.198 · Cited by 991
Intragenic ERBB2 kinase mutations in tumours
Stephens, P., Hunter, C., Bignell, G., Edkins, S., Davies, H., Teague, J., Stevens, C., O'Meara, S., Smith, R., Parker, A., et al. (2004) · Nature · doi:10.1038/431525b · Cited by 802
Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions.
Pinkas‐Kramarski, R., Soussan, L., Waterman, H., Levkowitz, G., Alroy, I., Klapper, L. N., Lavi, S., Seger, R., Ratzkin, B. J., Sela, M., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00603.x · Cited by 770
PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib
Engelman, J. A., Zejnullahu, K., Gale, C.-M., Lifshits, E., Gonzales, A. J., Shimamura, T., Zhao, F., Vincent, P. W., Naumov, G. N., Bradner, J. E., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1885 · Cited by 730

Show all 48 references

Sorted by citations

Items 101–200 of 506

Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study
Koga, T., Kobayashi, Y., Tomizawa, K., Suda, K., Kosaka, T., Sesumi, Y., Fujino, T., Nishino, M., Ohara, S., Chiba, M., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.10.019 · Cited by 70
Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial
Song, Z., Li, Y., Chen, S., Ying, S., Xu, S., Huang, J., Wu, D., Lv, D., Bei, T., Liu, S., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02245-z · Cited by 68
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance
Cretella, D., Saccani, F., Quaini, F., Frati, C., Lagrasta, C. A., Bonelli, M. A., Caffarra, C., Cavazzoni, A., Fumarola, C., Galetti, M., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-143 · Cited by 66
Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma
Tanaka, K., Hida, T., Oya, Y., Yoshida, T., Shimizu, J., Mizuno, T., Kuroda, H., Sakakura, N., Yoshimura, K., Horio, Y., et al. (2017) · Cancer · doi:10.1002/cncr.30539 · Cited by 68
Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC
Baraibar, I., Mezquita, L., Bazo, I. G., & Planchard, D. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102906 · Cited by 69
Personalized Therapy for Lung Cancer
Moreira, A. L., & Eng, J. (2014) · CHEST Journal · doi:10.1378/chest.14-0713 · Cited by 67
Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities
Yoda, S., Dagogo‐Jack, I., & Hata, A. N. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.007 · Cited by 68
Review of the current targeted therapies for non-small-cell lung cancer
Nguyen, K.-S. H. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i4.576 · Cited by 62
HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches.
Garrido-Castro, A. C., & Felip, E. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2013.02.02 · Cited by 63
Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives
Tomasello, C., Baldessari, C., Napolitano, M., Orsi, G., Grizzi, G., Bertolini, F., Barbieri, F., & Cascinu, S. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.01.013 · Cited by 65
Mutation Variants and Co-Mutations as Genomic Modifiers of Response to Afatinib in HER2-Mutant Lung Adenocarcinoma
Fang, W., Zhao, S., Liang, Y., Yang, Y., Yang, L., Dong, X., Zhang, L., Shoufeng, W., Yang, Y., Yang, Y., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0547 · Cited by 63
Analysis of different HER ‐2 mutations in breast cancer progression and drug resistance
Sun, Z., Shi, Y., Shen, Y., Cao, L., Zhang, W., & Guan, X. (2015) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12662 · Cited by 64
Mutational landscape and characteristics of ERBB2 in non‐small cell lung cancer
Wei, X., Gao, X., Zhang, X., Yang, J., Chen, Z., Wu, Y.-L. L. C., & Zhou, Q. H. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13419 · Cited by 62
Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer
Rebuzzi, S. E., Zullo, L., Rossi, G., Grassi, M., Murianni, V., Tagliamento, M., Prelaj, A., Coco, S., Longo, L., Bello, M. G. D., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052625 · Cited by 65
Molecular Pathways and Mechanisms of HER2 in Cancer Therapy
Raghav, K. P. S., & Moasser, M. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0283 · Cited by 65
New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1)
Russo, A., Lopes, A. R., McCusker, M. G., Garrigues, S. G., Ricciardi, G. R. R., Arensmeyer, K. E., Scilla, K. A., Mehra, R., & Rolfo, C. D. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00909-8 · Cited by 65
Targeting HER2 Exon 20 Insertion–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib
Han, H., Li, S., Chen, T., Fitzgerald, M., Liu, S., Peng, C., Tang, K. H., Cao, S., Chouitar, J., Wu, J., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1526 · Cited by 57
Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer
Dolly, S. O., Collins, D. C., Sundar, R., Popat, S., & Yap, T. A. (2017) · Drugs · doi:10.1007/s40265-017-0732-2 · Cited by 59
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program
Prelaj, A., Bottiglieri, A., Proto, C., Russo, G. L., Signorelli, D., Ferrara, R., Galli, G., Toma, A. D., Viscardi, G., Brambilla, M., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.02.038 · Cited by 58
Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer
Wang, Z., Xing, Y., Li, B., Li, X., Liu, B., & Wang, Y. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00107-x · Cited by 62
Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients
Hong, L., Patel, S. A., Drusbosky, L. M., Xiong, Y., Chen, R., Geng, R., Heeke, S., Nilsson, M. B., Wu, J., Heymach, J. V., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00720-9 · Cited by 62
Fine particle matters induce DNA damage and G2/M cell cycle arrest in human bronchial epithelial BEAS-2B cells
Wu, J., Shi, Y., Asweto, C. O., Feng, L., Yang, X., Zhang, Y., Hu, H., Duan, J., & Sun, Z. (2017) · Environmental Science and Pollution Research · doi:10.1007/s11356-017-0090-3 · Cited by 52
Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients
Papadopoulou, E., Τσούλος, Ν., Tsantikidi, K., Metaxa-Mariatou, V., Stamou, P. E., Kladi-Skandali, A., Kapeni, E., Tsaousis, G., Pentheroudakis, G. E., Petrakis, D., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0226853 · Cited by 55
Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion
Chu, Q. S.-C. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919895756 · Cited by 56
Novel Targets, Novel Treatments: The Changing Landscape of Non-Small Cell Lung Cancer
de Jong, D., Das, J. P., Ma, H., Valiplackal, J. P., Prendergast, C. M., Roa, T., Braumuller, B., Deng, A., Dercle, L., Yeh, R., et al. (2023) · Cancers · doi:10.3390/cancers15102855 · Cited by 55
Exon 20 YVMA insertion is associated with high incidence of brain metastasis and inferior outcome of chemotherapy in advanced non-small cell lung cancer patients with HER2 kinase domain mutations
Yang, S., Wang, Y., Zhao, C., Li, X., Liu, Q., Mao, S., Liu, Y., Yu, X., Wang, W., Tian, Q., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-559 · Cited by 60
Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers
Eng, J., Hsu, M., Chaft, J. E., Kris, M. G., Arcila, M. E., & Li, B. T. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.05.030 · Cited by 52
Self-citation
Lessons To Be Learned: The Molecular Basis of Kinase‐Targeted Therapies and Drug Resistance in Non‐Small Cell Lung Cancer
Lategahn, J., Keul, M., & Rauh, D. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201710398 · Cited by 52
Development of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the Onconetwork consortium
Tops, B. B. J., Normanno, N., Kurth, H. M., Amato, E., Mafficini, A., Rieber, N., Corre, D. L., Rachiglio, A. M., Reiman, A., Sheils, O. M., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1015-5 · Cited by 51
Management of HER2 alterations in non-small cell lung cancer – The past, present, and future
Nützinger, J., Lee, J. B., Low, J. L., Chia, P. L., Wijaya, S. T., Cho, B. C., Lim, S. M., & Soo, R. A. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107385 · Cited by 50
HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study
Heymach, J. V., Opdam, F. L., Barve, M. A., Tu, H., Wu, Y.-L. L. C., Berz, D., Schröter, L., Botilde, Y., Sadrolhefazi, B., Serra, J., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-01727 · Cited by 56
Targeted therapy for NSCLC with driver mutations
Minuti, G., D’Incecco, A., & Cappuzzo, F. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.827657 · Cited by 46
Conformational Landscapes of HER2 Exon 20 Insertions Explain Their Sensitivity to Kinase Inhibitors in Lung Adenocarcinoma
Zhao, S., Fang, W., Pan, H., Yang, Y., Liang, Y., Yang, L., Dong, X., Zhan, J., Wang, K., & Zhang, L. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.020 · Cited by 45
First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2 -altered NSCLC: a retrospective real-world POLISH study
Yang, G., Yang, Y., Liu, R., Li, W., Xu, H., Hao, X., Li, J., Xing, P., Zhang, S., Ai, X., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221082339 · Cited by 44
Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease
Yarden, Y., & Wheeler, D. L. (2014) · Springer eBooks · doi:10.1007/978-1-4939-2053-2 · Cited by 44
Cancer of the Lung
Araujo, L. H., Horn, L., Merritt, R. E., Shilo, K., Xu‐Welliver, M., & Carbone, D. P. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00069-4 · Cited by 47
Differentiating Separate Primary Lung Adenocarcinomas From Intrapulmonary Metastases With Emphasis on Pathological and Molecular Considerations: Recommendations From the International Association for the Study of Lung Cancer Pathology Committee
Chou, T., Dacic, S., Wistuba, I. I., Beasley, M. B., Berezowska, S., Chang, Y., Chung, J.-H., Connolly, C., Han, Y., Hirsch, F. R., et al. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.11.016 · Cited by 43
Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy
Singh, S. S., Dahal, A., Shrestha, L., & Jois, S. D. S. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190222183219 · Cited by 42
HER2-Altered Non-Small Cell Lung Cancer: Biology, Clinicopathologic Features, and Emerging Therapies
Yu, X., Ji, X., & Su, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.860313 · Cited by 45
Novel therapeutic strategies for rare mutations in non-small cell lung cancer
Gou, Q., Gou, Q., Gan, X., & Xie, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-61087-2 · Cited by 42
HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib
Li, B. T., Lee, A., O'Toole, S. A., Cooper, W., Yu, B., Chaft, J. E., Arcila, M. E., Kris, M. G., & Pavlakis, N. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.10.025 · Cited by 40
Self-citation
The genomic landscape of nonsmall cell lung carcinoma in never smokers
Boeckx, B., Shahi, R. B., Smeets, D., Brakeleer, S. D., Decoster, L., Brussel, T. V., Galdermans, D., Vercauter, P., Decoster, L., Alexander, P., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32797 · Cited by 40
HER2: An emerging biomarker in non-breast and non-gastric cancers
Omar, N., Yan, B., & Salto‐Tellez, M. (2015) · Pathogenesis · doi:10.1016/j.pathog.2015.05.002 · Cited by 40
Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC
Zer, A., & Leighl, N. B. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00329 · Cited by 39
Discovery of potential HER2 inhibitors from Mangifera indica for the treatment of HER2-Positive breast cancer: an integrated computational approach
Balogun, T. A., Iqbal, M. N., Saibu, O. A., Akintubosun, M. O., Lateef, O. M., Nneka, U. C., Abdullateef, O. T., & Omoboyowa, D. A. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1975570 · Cited by 41
Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2)
Yang, G., Xu, H., Yang, Y., Zhang, S., Xu, F., Hao, X., Li, J., Xing, P., Hu, X., Liu, Y., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02470-6 · Cited by 39
Construction of a prognostic model of luteolin for endometrial carcinoma.
Zhao, J., Jiao, W., Sui, X., Zou, J., Wang, J., & Lin, Z. (2023) · PubMed Central · Cited by 38
A consensus statement on the gender perspective in lung cancer
Isla, D., Majem, M., Viñolas, N., Artal, A., Blasco, A., Felip, E., Garrido, P., Remón, J., Baquedano, M., Borràs, J. M., et al. (2016) · Clinical & Translational Oncology · doi:10.1007/s12094-016-1578-x · Cited by 38
Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options
Brazel, D., Kroening, G., & Nagasaka, M. (2022) · BioDrugs · doi:10.1007/s40259-022-00556-4 · Cited by 37
The Genetic Analysis and Clinical Therapy in Lung Cancer: Current Advances and Future Directions
Rina, A., Maffeo, D., Minnai, F., Esposito, M., Palmieri, M., Serio, V. B., Rosati, D., Mari, F., Frullanti, E., & Colombo, F. (2024) · Cancers · doi:10.3390/cancers16162882 · Cited by 44
The Molecular Pathology of Lung Cancer
Sholl, L. M. (2016) · Surgical pathology clinics · doi:10.1016/j.path.2016.04.003 · Cited by 36
Impact of concurrent genomic alterations in epidermal growth factor receptor (EGFR)-mutated lung cancer
Gini, B., Thomas, N. J., & Blakely, C. M. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.03.78 · Cited by 38
Antibody-Drug Conjugates for Lung Cancer: Payloads and Progress
Rosner, S., Valdivia, A., Hoe, H. J., Murray, J. C., Levy, B. P., Felip, E., & Solomon, B. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_389968 · Cited by 35
EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates
Sentana‐Lledo, D., Academia, E. C., Viray, H., Rangachari, D., Kobayashi, S. S., VanderLaan, P. A., & Costa, D. B. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-98 · Cited by 34
The use of molecular imaging combined with genomic techniques to understand the heterogeneity in cancer metastasis
Chowdhury, R., Ganeshan, B., Irshad, S., Lawler, K., Eisenblätter, M., Milewicz, H., Rodriguez‐Justo, M., Miles, K. A., Ellis, P., Groves, A. M., et al. (2014) · BJR|case reports · doi:10.1259/bjr.20140065 · Cited by 34
Predicting Response to Antibody Drug Conjugates: A Focus on Antigens’ Targetability
Ascione, L., Crimini, E., Trapani, D., Marra, A., Criscitiello, C., & Curigliano, G. (2023) · The Oncologist · doi:10.1093/oncolo/oyad246 · Cited by 35
Personalized Therapy of Non-small Cell Lung Cancer (NSCLC)
Gadgeel, S. M. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-24932-2_11 · Cited by 32
Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland
Große, A., Große, C., Rechsteiner, M., & Soltermann, A. (2019) · Diagnostic Pathology · doi:10.1186/s13000-019-0789-1 · Cited by 35
Molecular features of lung adenocarcinoma in young patients
Chen, Z., Teng, X., Zhang, J., Huang, K., Shen, Q., Luo, H., Luo, H., Yuan, Y., & Teng, X. (2019) · BMC Cancer · doi:10.1186/s12885-019-5978-5 · Cited by 34
Targeting HER2 genomic alterations in non-small cell lung cancer
Zeng, J., Ma, W., Young, R. B., & Li, T. (2021) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2021.04.001 · Cited by 37
The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer
Nagasaka, M., Singh, V., Baca, Y., Sukari, A. W., Kim, C., Mamdani, H. M., Spira, A. I., Uprety, D., Bepler, G., Kim, E. S., et al. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.08.012 · Cited by 34
Clinical characterization of ERBB2 exon 20 insertions and heterogeneity of outcomes responding to afatinib in Chinese lung cancer patients
Liu, Z., Wu, L., Cao, J., Yang, Z., Zhou, C., Cao, L., Wu, H., Shen, H., Jin, M., Zhang, Y., et al. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s173391 · Cited by 33
Standardizing Biomarker Testing for Canadian Patients with Advanced Lung Cancer
Melosky, B. L., Blais, N., Cheema, P. K., Couture, C., Juergens, R. A., Kamel‐Reid, S., Tsao, M., Wheatley‐Price, P., Xu, Z., & Ionescu, D. N. (2018) · Current Oncology · doi:10.3747/co.25.3867 · Cited by 35
Lung Cancer in Never Smokers: Delving into Epidemiology, Genomic and Immune Landscape, Prognosis, Treatment, and Screening
Daylan, A. E. C., Miao, E., Tang, K., Chiu, G., & Cheng, H. (2023) · Lung · doi:10.1007/s00408-023-00661-3 · Cited by 32
Lung cancer in women: an overview with special focus on Spanish women
Remón, J., Molina‐Montes, E., Majem, M., Lianes, P., Isla, D., Garrido, P., Felip, E., Viñolas, N., de Castro, J., Artal, A., et al. (2013) · Clinical & Translational Oncology · doi:10.1007/s12094-013-1137-7 · Cited by 32
HER2 mutations in Chinese patients with non-small cell lung cancer
Song, Z., Yu, X., Shi, Z., Zhao, J., & Zhang, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.11313 · Cited by 32
Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma
Oh, I., Hur, J. Y., Park, C., Kim, Y., Kim, S. J., Lee, M. K., Kim, H. J., Lee, K. Y., Lee, J. C., & Choi, C. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.05.018 · Cited by 32
Targeting the EGF receptor family in non-small cell lung cancer—increased complexity and future perspectives
Boch, T., Köhler, J., Janning, M., & Loges, S. (2022) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2022.0540 · Cited by 32
Suppressor of cytokine signalling-2 limits IGF1R-mediated regulation of epithelial–mesenchymal transition in lung adenocarcinoma
Zhou, Y., Zhang, Z., Wang, N., Chen, J., Zhang, X., Guo, M., Li, J. Z., & Wang, Q. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0457-5 · Cited by 33
Lung adenocarcinoma in the era of targeted therapies: histological classification, sample prioritization, and predictive biomarkers
Conde, E., Angulo, B., Izquierdo, E., Paz-Ares, L. G., Belda-Iniesta, C., Hidalgo, M. M., & López‐Ríos, F. (2013) · Clinical & Translational Oncology · doi:10.1007/s12094-012-0983-z · Cited by 31
Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?
Ou, S. I. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2012-201296 · Cited by 31
Clinical outcomes of patients with HER2 -mutant advanced lung cancer: chemotherapies versus HER2 -directed therapies
Zhou, J., Ding, N., Xu, X., Zhang, Y., Ye, M., Li, C., & Hu, J. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920936090 · Cited by 31
Discovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant Inhibitor
Jang, J., Son, J., Park, E., Kosaka, T., Saxon, J. A., Clercq, D. J. H. D., Choi, H. G., Tanizaki, J., Eck, M. J., Janne, P. A., et al. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201805187 · Cited by 32
Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC
Bansal, P., Osman, D. I., Gan, G. N., Simon, G. R., & Boumber, Y. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00112 · Cited by 31
HER2 and Src co-regulate proliferation, migration and transformation by downstream signaling pathways in arsenite-treated human uroepithelial cells
Zhou, Q., Jin, P., Liu, J., Wang, F., & Xi, S. (2018) · Metallomics · doi:10.1039/c8mt00131f · Cited by 30
Treatment outcome and clinical characteristics of HER2 mutated advanced non‐small cell lung cancer patients in China
Xu, F., Yang, G., Xu, H., Yang, L., Qiu, W., Li, J., & Wang, Y. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13317 · Cited by 29
A novel method to detect mutation in DNA by utilizing exponential amplification reaction triggered by the CRISPR-Cas9 system
Song, J., Kim, S., Kim, H. Y., Hur, K. H., Kim, Y., & Park, H. G. (2021) · Nanoscale · doi:10.1039/d1nr00438g · Cited by 30
Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer
Kumar, M., Ernani, V., & Owonikoko, T. K. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2015.06.009 · Cited by 31
ECT 2 amplification and overexpression as a new prognostic biomarker for early‐stage lung adenocarcinoma
Murata, Y., Minami, Y., Iwakawa, R., Yokota, J., Usui∥, S., Tsuta, K., Shiraishi, K., Sakashita, S., Satomi, K., Iijima, T., et al. (2014) · Cancer Science · doi:10.1111/cas.12363 · Cited by 30
Lung Adenocarcinoma With MUC4 Expression Is Associated With Smoking Status, HER2 Protein Expression, and Poor Prognosis: Clinicopathologic Analysis of 338 Cases
Rokutan‐Kurata, M., Yoshizawa, A., Sumiyoshi, S., Sonobe, M., Menju, T., Momose, M., Koyama, M., Shigeto, S., Fujimoto, M., Zhang, M., et al. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.11.013 · Cited by 30
The End of Nihilism: Systemic Therapy of Advanced Non–Small Cell Lung Cancer
Ernani, V., Steuer, C. E., & Jahanzeb, M. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-042915-102442 · Cited by 29
Targeting Receptor Tyrosine Kinases in Cancer
Köstler, W. J., & Zielinski, C. C. (2014) · Springer eBooks · doi:10.1007/978-1-4939-2053-2_10 · Cited by 26
Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists
Bui, K. T., Cooper, W. A., Kao, S., & Boyer, M. J. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7080192 · Cited by 29
Molecular charcterization of lung adenocarcinoma combining whole exome sequencing, copy number analysis and gene expression profiling
Testa, U., Pelosi, E., & Castelli, G. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2022.2017774 · Cited by 28
Therapeutic Potential of Afatinib for Cancers with ERBB2 (HER2) Transmembrane Domain Mutations G660D and V659E
Yamamoto, H., Toyooka, S., Ninomiya, T., Matsumoto, S., Kanai, M., Tomida, S., Kiura, K., Muto, M., Suzawa, K., Desmeules, P., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0345 · Cited by 28
Self-citation
Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions
Morita, C., Yoshida, T., Shirasawa, M., Masuda, K., Matsumoto, Y., Shinno, Y., Yagishita, S., Okuma, Y., Goto, Y., Horinouchi, H., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-98275-3 · Cited by 30
Efficacy of targeted therapy in patients with HER2‐positive non‐small cell lung cancer: A systematic review and meta‐analysis
Wu, H., Zhuo, K., & Wang, K. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15155 · Cited by 26
Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer
Henegouwen, J. M. V. B., Jebbink, M., Hoes, L. R., van der Wijngaart, H., Zeverijn, L. J., Velden, D. L. V. D., Roepman, P., de Leng, W. W. J., Jansen, A. M. L., van Werkhoven, E. D., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.05.009 · Cited by 28
Emerging protein kinase inhibitors for non-small cell lung cancer
Liu, S. V., Subramaniam, D. S., Cyriac, G., Khalek, F. J. A., & Giaccone, G. (2013) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2014.873403 · Cited by 28
Hot spot mutations in Finnish non-small cell lung cancers
Mäki‐Nevala, S., Sarhadi, V. K., Rönty, M. J., Kettunen, E., Husgafvel‐Pursiainen, K., Wolff, H. J., Knuuttila, A., & Knuutila, S. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.06.024 · Cited by 28
Rare Mutations in Non-Small-Cell Lung Cancer
D’Arcangelo, M., D’Incecco, A., & Cappuzzo, F. (2013) · Future Oncology · doi:10.2217/fon.13.16 · Cited by 26
Structure Defines Function: Clinically Relevant Mutations in ErbB Kinases
Niggenaber, J., Hardick, J., Lategahn, J., & Rauh, D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00964 · Cited by 27
HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
Gan, J., Huang, Y., Liao, J., Pang, L., & Fang, W. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s335217 · Cited by 27
Recent Progress in HER2 Associated Breast Cancer
Wang, W., Lei, Y., Mei, J. H., & Wang, C. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.7.2591 · Cited by 26
Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China
Li, X., Zhao, C., Su, C., Ren, S., Chen, X., & Zhou, C. (2016) · BMC Cancer · doi:10.1186/s12885-016-2875-z · Cited by 26
Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma
Salgia, R. (2016) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2016.1181545 · Cited by 25
Synthesis, crystal structure and activity evaluation of novel 3,4-dihydro-1-benzoxepin-5(2 H )-one derivatives as protein–tyrosine kinase (PTK) inhibitors
Li, N., Yao, B.-R., Wang, C., Meng, Q.-G., & Hou, G. (2017) · Acta Crystallographica Section C Structural Chemistry · doi:10.1107/s2053229617015145 · Cited by 25
Testing EGFR with Idylla on Cytological Specimens of Lung Cancer: A Review
Caputo, A., D’Ardia, A., Sabbatino, F., Picariello, C., Ciaparrone, C., Zeppa, P., & D’Antonio, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094852 · Cited by 25
Insight into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild Type-Sparing Inhibitors
Lategahn, J., Tumbrink, H. L., Schultz‐Fademrecht, C., Heimsoeth, A., Werr, L., Niggenaber, J., Keul, M., Parmaksiz, F., Baumann, M., Menninger, S., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02080 · Cited by 24
A review of recent advances in the novel therapeutic targets and immunotherapy for lung cancer
Khadela, A. D., Postwala, H. I., Rana, D. K., Dave, H., Ranch, K. M., & Boddu, S. H. S. (2023) · Medical Oncology · doi:10.1007/s12032-023-02005-w · Cited by 24

Authors: Arcila, M. E., Chaft, J. E., Nafa, K., Roy-Chowdhuri, S., Lau, C., Zaidinski, M., Paik, P. K., Zakowski, M. F., Kris, M. G., & Ladanyi, M.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
Authors' Affiliations: 1Department of Pathology, and 2Thoracic Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York
National Institutes of Health (US)
Corresponding author: Arcila, Maria E.
ORCID: Arcila, Maria E.
Chaft, Jamie E.
Zaidinski, Michael
Paik, Paul K.
Zakowski, Maureen F.
Kris, Mark G.
Ladanyi, Marc
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2012-09-15
Volume: 18
Issue: 18
Pages: 4910-4918
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-12-0912
PMC: PMC3865806
OpenAlex: W2107562400
Cited by: 505
References: 48
Citations by year: 2026: 17 · 2025: 38 · 2024: 36 · 2023: 40 · 2022: 39 · 2021: 52 · 2020: 42 · 2019: 30 · 2018: 42 · 2017: 30 · 2016: 23 · 2015: 43 · 2014: 37 · 2013: 31 · 2012: 4
FWCI: 29.67
Type: journal article
Language: en
Open access: green
europepmc.org
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: Memorial Sloan-Kettering Cancer Center
National Institutes of Health
National Cancer Institute (P01CA129243, T32CA009207, R25CA020449)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: HER2 mutation, lung adenocarcinoma, tyrosine kinase mutations, exon 20 insertion, never smokers, HER2 amplification, EGFR, KRAS, ALK rearrangement, molecular subtyping, clinicopathological features, molecular heterogeneity
MeSH terms: Adenocarcinoma, Adult, Aged, Aged, 80 and over, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasm Staging, Prognosis, Risk Factors, Prevalence, Survival Analysis, Erb-b2 Receptor Tyrosine Kinases, Receptor, ErbB-2, Protein Interaction Domains and Motifs, DNA Copy Number Variations

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 ( HER2 ) Tyrosine Kinase Mutations in Lung Adenocarcinomas

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks